Skip to content

The Longevity Industry Is Building Its Own Rules | Longevity News Roundup - Week 33, 2026

August 15, 2026 · 19 min

Show notes

Sponsor: FlexBeam


FlexBeam is a wearable red light therapy system that brings targeted support directly to where you need it most. Lightweight, portable, and easy to use, it fits naturally into your daily routine, making recovery and self-care more accessible whether you're at home, traveling, or between activities.


Click the link below to learn more and use code LONGEVITY.TECHNOLOGY for 10% off.

Link: rechargehealthas.sjv.io/jRQyQ5


----------

In this week’s Longevity News Roundup, Phil Newman examines how longevity is developing the clinical standards, biological models and infrastructure needed to move from promising technology toward real-world medicine.


  • Viome’s acquisition of Circulate Health brings therapeutic plasma exchange into a platform built around diagnostics, nutrition and coaching. Circulate’s network spans more than 200 partner clinics, creating a “measure, act, remeasure” model, while recent data on microplastics and biological age highlight the gap between measurable changes and proven healthspan outcomes.
  • Longevity Clinics World and the Healthy Longevity Medicine Society have signed an MOU focused on evidence-based medicine, shared terminology, education, quality improvement and standardization. The collaboration also emphasizes that future accreditation must have separate governance and independent oversight.
  • Kailera Therapeutics reported an active IND for ribupatide oral, with initiation of global Phase 3 obesity trials planned for the first half of 2027, and says its ribupatide injection Phase 2b high-dose obesity trial is fully enrolled with data anticipated in mid-2027; global Phase 3 KaiNETIC enrollment is on track for more than 4,700 participants with data expected in 2028.
  • Immorta Bio proposes combining multi-omics, AI, digital twins and secure patient-owned data into a continuously learning precision-medicine system. Exploratory metabolomic data from more than 2,000 individuals identified nine metabolites associated with age.
  • Insilico Medicine is developing its Virtual Aging Cell platform to model biological change across six interconnected scales, making biological age a core variable rather than simply an output. The key question is whether these simulations can generate predictions that survive experimental and clinical validation.


----------

News & References:



----------

Hosts:

Phil Newman: https://qrco.de/bgXpNY

All episodes of Longevity.Technology UNLOCKED

Settings

Display

Language

Decides which stations you see first on the home page.

History

Recently played stations and episodes and your latest searches are only stored in this browser.

Notifications

A short notice when a podcast you follow has a new episode. Turn off single podcasts with the bell on their page.

Account

Save favorites – in the app and on the website.

Keyboard shortcuts

/
Open search
Space
Play or pause
← →
In the player: back 15 s, forward 30 s (episodes) · in a row: next tile
↑ ↓
In a row: target within the tile
Home / End
In a row: first or last tile
Esc
Close window or menu
?
This overview
Now playing

Go to station page

Play next

    Add episodes with “Play next” – they play after the current episode.